NL-OMON49424已完成2 期
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501 - Safety and Efficacy of RGX-501
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 2
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •To be eligible to participate in this study, a participant must have previously
- •received RGX-501 in a
- •separate parent trial, and the participant or participant*s legal guardian(s)
- •is/(are) willing and able to
- •provide written, signed informed consent after the nature of the study has been
- •explained, prior to any
- •research-related procedures.
排除标准
- •see inclusion criteria
研究者
相似试验
进行中（未招募）
1 期
A long-term follow-up study to evaluate the safety and efficacy of retinal gene therapy in subjects with Choroideremia previously treated with AAV2-REP1 and in subjects with X-Linked Retinitis Pigmentosa previously treated with AAV8-RPGR in an antecedent studyEUCTR2017-003104-42-DEightstaRx Ltd (A Biogen Company)330
进行中（未招募）
1 期
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501EUCTR2019-004496-39-NLREGENXBIO Inc.12
进行中（未招募）
1 期
A long-term follow-up study to evaluate the safety and efficacy of retinal gene therapy in subjects with Choroideremia previously treated with AAV2- REP1 in an antecedent study and in subjects with X-Linked Retinitis Pigmentosa previously treated with AAV8-RPGR in an antecedent studyChoroideremia (CHM)X-Linked Retinitis Pigmentosa (XLRP)MedDRA version: 20.1Level: LLTClassification code 10008791Term: ChoroideremiaSystem Organ Class: 100000004853MedDRA version: 20.0Level: PTClassification code 10038914Term: Retinitis pigmentosaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-003104-42-DKightstaRx Ltd (A Biogen Company)330
进行中（未招募）
1 期
A long-term follow-up study to evaluate the safety and efficacy of retinal gene therapy in subjects with Choroideremia previously treated in an antecedent studyChoroideremia (CHM)EUCTR2017-003104-42-NLightstaRx Ltd167
尚未招募
3 期
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Previously Treated with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1)
and in Subjects with X-Linked Retinitis Pigmentosa Previously Treated with Adeno-Associated Viral Vector Encoding RPGR (AAV8-RPGR) in an Antecedent Study2023-507994-16-00Biogen Idec Research Limited54